Nuvalent Inc (NUVL)

Official site

BIOTECHNOLOGY

$123.96

+0.00 (+0.00%)

Last updated: Jul 16, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

35%(7/20)

Avg Surprise

-86.08%

Upcoming Estimates

Period ending Jun 30, 2026

EPS Consensus$-1.38

Range$-1.48 - $-1.13

9 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$-1.37-0.5%

60d ago$-1.38-0.1%

30d ago$-1.37-0.7%

7d ago$-1.37-0.7%

Current$-1.38

Revenue Consensus

Range$0 - $0

9 analysts

Period ending Sep 30, 2026

EPS Consensus$-1.40

Range$-1.57 - $-1.21

9 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$-1.39-0.8%

60d ago$-1.40-0.3%

30d ago$-1.39-1.0%

7d ago$-1.39-1.0%

Current$-1.40

Revenue Consensus

$1M

Range$0 - $6M

9 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-1.42	$-2.28 - $-0.61	-	-	10	-	-
Sep 30, 2026Sep 26EST	-	$-1.40	$-1.57 - $-1.21	-	-	9	0 2 30d	-
Jun 30, 2026Jun 26EST	-	$-1.38	$-1.48 - $-1.13	-	-	9	0 2 30d	-
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$-1.39	$-1.31	$-1.60 - $-0.95	-6.11%	Miss	13	7 0 30d	-17.8%
Dec 31, 2025Dec 25 Reported Feb 26, 2026Reported Feb 26	$-1.29	$-1.48	$-1.59 - $-1.14	+12.84%	Beat	15	1 0 30d	-22.9%
Sep 30, 2025Sep 25 Reported Oct 30, 2025Reported Oct 30	$-1.70	$-1.32	$-1.50 - $-1.03	-28.79%	Miss	13	1 7 30d	-32.8%
Jun 30, 2025Jun 25 Reported Aug 7, 2025Reported Aug 7	$-1.31	$-1.27	$-1.38 - $-0.91	-3.15%	Miss	8	1 8 30d	-48.9%
Mar 31, 2025Mar 25 Reported May 8, 2025Reported May 8	$-1.18	$-1.13	$-1.26 - $-0.76	-4.42%	Miss	9	1 4 30d	-71.0%
Dec 31, 2024Dec 24 Reported Feb 27, 2025Reported Feb 27	$-1.05	$-1.05	$-1.33 - $-0.70	+0.00%	Beat	12	3 7 30d	-69.4%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-1.28	$-0.89	$-1.14 - $-0.78	-43.82%	Miss	12	No revisions (30d)	-116.9%
Jun 30, 2024Jun 24 Reported Aug 8, 2024Reported Aug 8	$-0.88	$-0.74	$-0.86 - $-0.59	-18.92%	Miss	10	No revisions (30d)	-72.5%
Mar 31, 2024Mar 24 Reported May 9, 2024Reported May 9	$-0.69	$-0.64	$-0.79 - $-0.54	-7.81%	Miss	9	No revisions (30d)	-56.8%
Dec 31, 2023Dec 23 Reported Feb 27, 2024Reported Feb 27	$-0.62	$-0.60	$-0.68 - $-0.54	-3.33%	Miss	8	No revisions (30d)	-26.5%
Sep 30, 2023Sep 23 Reported Nov 14, 2023Reported Nov 14	$-0.59	$-0.57	$-0.66 - $-0.52	-3.51%	Miss	8	No revisions (30d)	-43.9%
Jun 30, 2023Jun 23 Reported Aug 10, 2023Reported Aug 10	$-0.51	$-0.51	$-0.58 - $-0.45	+0.00%	Beat	7	No revisions (30d)	-34.2%
Mar 31, 2023Mar 23 Reported May 11, 2023Reported May 11	$-0.44	$-0.49	$-0.55 - $-0.47	+10.20%	Beat	5	No revisions (30d)	-22.2%
Dec 31, 2022Dec 22 Reported Mar 16, 2023Reported Mar 16	$-0.49	$-0.43	$-0.47 - $-0.36	-13.95%	Miss	5	No revisions (30d)	-36.1%
Sep 30, 2022Sep 22 Reported Nov 10, 2022Reported Nov 10	$-0.41	$-0.45	$-0.51 - $-0.40	+8.89%	Beat	3	No revisions (30d)	-5.1%
Jun 30, 2022Jun 22 Reported Aug 10, 2022Reported Aug 10	$-0.38	$-0.42	$-0.44 - $-0.39	+9.52%	Beat	4	No revisions (30d)	+88.0%
Mar 31, 2022Mar 22 Reported May 12, 2022Reported May 12	$-0.36	$-0.39	$-0.42 - $-0.37	+7.69%	Beat	3	No revisions (30d)	+12.2%
Dec 31, 2021Dec 21 Reported Mar 29, 2022Reported Mar 29	$-0.36	$-0.32	$-0.34 - $-0.30	-12.50%	Miss	3	No revisions (30d)	+84.9%
Sep 30, 2021Sep 21 Reported Nov 10, 2021Reported Nov 10	$-0.39	$-0.25	$-0.28 - $-0.22	-56.00%	Miss	3	No revisions (30d)	-213.6%
Jun 30, 2021Jun 21 Reported Jul 30, 2021Reported Jul 30	$-3.17	$-0.19	$-0.22 - $-0.17	-1568.42%	Miss	2	No revisions (30d)	-
Mar 31, 2021Mar 21 Reported Jun 2, 2021Reported Jun 2	$-0.41	$0.00	-	N/A	Miss	-	-	-
Dec 31, 2020Dec 20 Reported Mar 31, 2021Reported Mar 31	$-2.39	$0.00	-	N/A	Miss	-	-	-
Dec 31, 2019Dec 19 Reported Mar 30, 2020Reported Mar 30	$0.34	$0.00	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	N/A	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	N/A	Operating Margin	N/A
ROE	N/A	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	N/A	Quick Ratio	N/A
Trading Statistics
Beta	N/A	Avg Volume	N/A
52-Week High	N/A	52-Week Low	N/A

Technical Indicators Dashboard

Moving Averages

SMA 10$123.86

SMA 20$123.67

SMA 50$112.65

SMA 200$103.65

EMA 10$123.70

EMA 20$121.88

EMA 50$115.59

EMA 200$102.91

MACD

Line: 3.04Signal: 3.79Hist: -0.75

ADX

ADX: 35.0+DI: 42.9-DI: 19.1

Aroon & PSAR

Aroon Up92.0

Aroon DownN/A

PSAR$116.58

Bollinger Bands

Upper Band$124.09

Lower Band$123.26

%B Position67%(Middle)

Band Width0.85

RSI (14-Day)

Neutral

67.6

Momentum Oscillators

Stoch %K94.6

Stoch %D95.0

Williams %R-5.4

ROC (10d)0.3%

Momentum0.36

CCI (20d)110.9

MFI (14d)65.0

Volatility Measures

ATR (14d)$1.18(0.9%)

StdDev (20d)0.21

Hist Vol0.7%(Low)

Volume Flow

VWAP$123.96

OBV69.8M

AD Line3.7M

CMF (20d)-0.039

Volume Metrics

Avg Vol (20d)1.9M

Vol RatioN/A

VWMA (20d)$123.62

Pivot Points

R3$123.96

R2$123.96

R1$123.96

Pivot Point$123.96

S1$123.96

S2$123.96

S3$123.96

Advanced Oscillators

TSI34.04

Ultimate Osc67.6

KST129.48

Financial Data

Quarter	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Cost of Revenue	$0	N/A	$0	$0	$0	N/A	$0	$0	$0	N/A	$0	$0
Gross Profit	$0	N/A	$0	$0	$0	N/A	$0	$0	$0	N/A	$0	$0

Operating Expenses	$119.41M	$102.23M	$112.70M	$104.57M	$94.81M	$86.30M	$76.33M	$65.15M	$52.59M	$46.44M	$38.78M	$34.06M
R&D	$83.61M	$67.80M	$83.84M	$80.91M	$74.42M	$69.42M	$60.55M	$49.17M	$38.63M	$35.59M	$29.61M	$25.92M
SG&A	$35.80M	$34.43M	$28.85M	$23.66M	$20.39M	$16.88M	$15.78M	$15.98M	$13.95M	$10.85M	$9.17M	$8.14M
Operating Income	$-119,407,000	$-102,228,000	$-112,696,000	$-104,571,000	$-94,812,000	$-86,299,000	$-76,331,000	$-65,150,000	$-52,588,000	$-46,437,000	$-38,783,000	$-34,062,000

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$16.33M	$9.61M	$0	$0	$0	$7.97M	$0	$0	$0	$0	$0
Income Before Tax	$-109,111,000	$-118,554,000	$-122,305,000	$-99,508,000	$-84,425,000	$-74,592,000	$-84,305,000	$-56,996,000	$-44,099,000	$-38,292,000	$-33,645,000	$-29,090,000
Income Tax Expense	$168,000	$151,000	$132,000	$145,000	$157,000	$171,000	$40,000	$170,000	$383,000	$0	$0	$0

Net Income	$-109,279,000	$-118,705,000	$-122,437,000	$-99,653,000	$-84,582,000	$-74,763,000	$-84,345,000	$-57,166,000	$-44,482,000	$-38,292,000	$-33,645,000	$-29,090,000

EBITDA	$-121,237,000	$-104,158,000	$-114,883,000	$-107,278,000	$-99,095,000	$-91,232,000	$-79,252,000	$-60,429,000	$-47,481,000	$-48,529,000	$-41,413,000	$-36,911,000
EBIT	$-119,407,000	$-102,228,000	$-112,696,000	$-104,571,000	$-94,812,000	$-86,299,000	$-76,331,000	$-56,996,000	$-44,099,000	$-46,437,000	$-38,783,000	$-34,062,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about NUVL

News

Price to sales forward of Nuvalent, Inc. Class A – LS:A3CWDU

This article provides financial data for Nuvalent, Inc. Class A (LS:A3CWDU) focusing

TradingView•Aug 4, 2026 8:39 AM ET8/4/26•Neutral

Enterprise value to EBIT forward of Nuvalent, Inc. Class A – LS:A3CWDU

This article provides financial information for Nuvalent, Inc. Class A (LS:A3CWDU), specifically its enterprise value to EBIT forward. It is presented on the TradingView platform...

TradingView•Aug 3, 2026 5:43 PM ET8/3/26•Neutral

Price to earnings forward of Nuvalent, Inc. Class A – LSX:A3CWDU

This page provides financial information for Nuvalent, Inc. Class A (LSX:A3CWDU), specifically its forward price-to-earnings ratio. The data presented is from TradingView...

TradingView•Aug 1, 2026 11:11 PM ET8/1/26•Neutral

Price to book forward of Nuvalent, Inc. Class A – LS:A3CWDU

This article provides financial data for Nuvalent, Inc. Class A (LS:A3CWDU), focusing on its "Price to book forward" metric. It appears to be a snapshot from a financial data platform like TradingView...

TradingView•Jul 29, 2026 11:09 PM ET7/29/26•Neutral

Price to book forward of Nuvalent, Inc. Class A – LSX:A3CWDU

This article provides financial information for Nuvalent, Inc. Class A, traded on the Lang & Schwarz Exchange under the symbol A3CWDU. It focuses on the "Price to book forward" metric...

TradingView•Jul 29, 2026 10:10 PM ET7/29/26•Neutral

NUVL Competitors

Company	Ticker
Bio-Rad Laboratories Inc	BIO-B
Bio-Rad Laboratories Inc	BIO
Twist Bioscience Corp	TWST
Krystal Biotech Inc	KRYS
The Ensign Group Inc	ENSG
Henry Schein Inc	HSIC
Apogee Therapeutics, Inc. Common Stock	APGE
10X Genomics Inc	TXG

Sector: Healthcare

NUVL Bull Case vs Bear Case

Bear case

NUVL beat EPS estimates in 12.5% of its last 8 reported quarters.

NUVL Earnings: Beat Rate and Next Report

Beat rate: 1 of 8 quarters (12.5%)
Average surprise: -11.5%
EPS estimate (fiscal period ending Jun 30, 2026): $-1.38
Estimate revisions (30 days, fiscal period ending Jun 30, 2026): 0 up, 2 down

Frequently Asked Questions About NUVL

Does NUVL pay dividends?

Nuvalent Inc (NUVL) does not currently pay a regular dividend.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In

Earnings

Performance (10Y)

Upcoming Estimates

Key Metrics

Technical Indicators Dashboard

Moving Averages

MACD

ADX

Aroon & PSAR

Bollinger Bands

RSI (14-Day)

Momentum Oscillators

Volatility Measures

Volume Flow

Volume Metrics

Pivot Points

Advanced Oscillators

Financial Data

Related GNG Research

News

Price to sales forward of Nuvalent, Inc. Class A – LS:A3CWDU

Enterprise value to EBIT forward of Nuvalent, Inc. Class A – LS:A3CWDU

Price to earnings forward of Nuvalent, Inc. Class A – LSX:A3CWDU

Price to book forward of Nuvalent, Inc. Class A – LS:A3CWDU

Price to book forward of Nuvalent, Inc. Class A – LSX:A3CWDU

NUVL Competitors

NUVL Bull Case vs Bear Case

Bear case

NUVL Earnings: Beat Rate and Next Report

Frequently Asked Questions About NUVL

Related stocks

Get full access to GNG Research